Pharmacovigilance Raised As Part Of GDUFA III
GDUFA III May Be Opportunity For Proactive Pharmacovigilance Discussions
Generics sponsors want FDA input before making decisions on pharmacovigilance problems, potentially adding another topic to user fee discussions.
